Mainz Biomed's Mid-2025 Update: Strategic Moves in Cancer Screening

Mainz Biomed N.V. has made significant strides in 2025. The US-based company is advancing its FDA Premarket Approval Study for a new colorectal cancer screening product. Furthermore, Mainz has acquired a strategic interest in pancreatic cancer screening. The first half of the year saw the launch of eAArly DETECT 2, a US feasibility study on colorectal cancer screening, covering 2,000 patients using mRNA biomarkers and AI algorithms.

In addition, Mainz Biomed expanded its international presence through significant partnerships. They have launched ColoAlert®, a DNA-based test in Switzerland, and are collaborating with EDX Medical Group in the UK. Their partnership with Liquid Biosciences focuses on a non-invasive blood test for pancreatic cancer, showing a promising 95% sensitivity and 98% specificity.

Mainz also received public funding for its PancAlert project for pancreatic cancer, with up to 50% of project costs covered by German state funding, a testament to its potential societal value.